Table 3.

Features of pazopanib-induced hypertension in the 20 patients in which it developed

Parameter	Value	Range
Change in systolic BP (mm Hg)	8.2 [−3.7–18.4]	−54.6-26.3
Change in diastolic BP (mm Hg)	5.6 [0.4–11.4]	−8.3–18.2
Maximal systolic BP (mm Hg)	167.5 [159.5–186.5]	148–195
Maximal diastolic BP (mm Hg)	96 [92–106.5]	80–112
Time until pazopanib-induced HTN (days)	24.5 [14.5–53.5]	7–641
Antihypertensive dose increased or new agent added	17 (85)
No preexisting HTN	6 (30)
Class of antihypertensive started or intensified
ACEIs or ARBs	12 (46)
Beta-blockers	3 (12)
Calcium channel blockers	7 (27)
Diuretics	1 (4)
Others*	3 (12)

BP blood pressure, HTN hypertension, n number, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker

Data presented as a number with percent (%) or median [1st quartile-3rd quartile]

^*Clonidine (n = 2) and hydralazine (n = 1)